18085-97-7
18085-97-7 结构式
基本信息
爵筛奥素
棕矢车菊素
JACOSIDIN
棕矢车菊素对照品,
棕矢车菊素、合金欢素
棕矢车菊素(标准品)
棕矢车菊素(合金欢素,爵筛奥素)
4',5,7-三羟基-3',6-二甲氧基黄酮
4',5,7-三羟基-3',6-二甲氧基苯并吡喃-4-酮
Jaseosidin
JACEOSIDIN
Jacesiolin
6-Hydroxyluteolin 3',6-dimethyl ether
4',5,7-Trihydroxy-3',6-dimethoxyflavone
3',6-Dimethoxy-4',5,7-trihydroxyflavone
5,7-dihydroxy-2-(4-hydroxy-3-methoxy-phenyl)-6-methoxy-chromen-4-one
5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-methoxy-4H-chromen-4-one
5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-methoxy-4H-1-benzopyran-4-one
物理化学性质
常见问题列表
从艾叶中分离得到的棕矢车菊素和异泽兰黄素属于环烯醚萜苷类，其主要具有清热、镇痛等相关活性作用。
|
Bax
|
COX-2
|
Jaceosidin (30, 50, 75 μM) induces apoptosis in human renal carcinoma Caki cells after treatment for 24 h, shows no obvious effect on normal cells.
Jaceosidin (75 μM) reduces MMP levels and causes cytochrome c release into the cytoplasm through Bax activation.
Jaceosidin-mediated apoptosis is involved in downregulation of Mcl-1, c-FLIP expression, which is via inhibition of NF-κB and/or Sp1 transcriptional activity.
Jaceosidin shows cytostatic activity to HES and HESC cells with IC
50
s of 52.68 and 55.10 μM, and is less cytotocxic on Hec1 A and KLE (IC
50
, 70.54, 147.14 μM, respectively), after treatment for 48 h.
Cell Viability Assay
| Cell Line: | Hec1A, KLE, HES and HESC cells |
| Concentration: | 3.125, 6.25, 12.5, 25, 50, and 100 μM |
| Incubation Time: | 48 hour |
| Result: | Showed cytostatic activity to HES and HESC cells with IC 50 s of 52.68 and 55.10 μM, less cytotocxic on Hec1 A and KLE (IC 50 , 70.54, 147.14 μM). |
Jaceosidin (10 and 20 mg/kg, p.o., once a day for 3 days) blocks carrageenan-induced increase in leukocyte number and protein levels in air pouch exudates in mice.
Jaceosidin (10, 20 mg/kg, p.o.) suppresses COX-2 expression and NF-κB activation in mice.
Jaceosidin (20 mg/kg, p.o. for 2 hours) reduces hind paw edema volume in rats.
| Animal Model: | 5-week-old male BALB/c mice (23-26 g) |
| Dosage: | 10 and 20 mg/kg |
| Administration: | P.O. once a day for 3 days |
| Result: | Decreased the volumes of exudates (inflammatory markers), cell number and protein levels. Inhibited TNF-α by 46.7% and 50.8%, IL-1β by 46.0% and 44.7%, and PGE2 by 21.7% and 16.9%, respectively, at 20 mg/kg. Blocked COX-2 expression and NF-κB activation. |
| Animal Model: | Male Sprague-Dawley rats (180-200 g) |
| Dosage: | 20 mg/kg |
| Administration: | P.O., for 2 hour |
| Result: | Reduced hind paw edema volume by 27.1% at 1 h, and 24.0% at 2 h, respectively. |